CIP2A is a potential biomarker for disease progression and treatment failure in CML-CP

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.

Key clinical point: High cancerous inhibitor of protein phosphatase 2A (CIP2A) levels at diagnosis predicts subsequent disease progression and treatment failure in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib or dasatinib.

Major finding: High vs. low CIP2A levels were associated with poor progression-free survival (P = .04) and freedom from progression (P = .03). Patients with high vs. low CIP2A levels had a higher chance of treatment failure at 5 years (41% vs. 7.5%; P = .002) in both imatinib- (45% vs. 11%; P = .02) and dasatinib-treated (36% vs. 4%; P = .007) patients.

Study details: Data come from an analysis of 172 patients with newly diagnosed CML-CP enrolled in phase 3 SPIRIT2 trial who were randomly allocated to frontline imatinib (n=90) or dasatinib (n=82).

Disclosures: This study was funded by Bristol Myers Squibb (BMS). The lead author reported research support and/or honoraria from Novartis, BMS, and Pfizer. Other authors declared no conflicts of interest.

Source: Clark RE et al. Cancers (Basel). 2021 Apr 29. doi: 10.3390/cancers13092155.